Core Insights - Novo Nordisk (NVO.US) shares rose by 5% to $61.13 following a Medicare data study involving nearly 60,000 diabetes and heart disease patients [1] - The study revealed that patients using Novo Nordisk's diabetes drug Ozempic had a 23% lower risk of heart attack, stroke, or death compared to those using Eli Lilly's Trulicity [1] - This finding is significant for Novo Nordisk as it strengthens its position in the competitive weight-loss drug market against Eli Lilly, which is gaining market share with its newer drugs Mounjaro and Zepbound [1]